Manages edema and sodium retention. ANDA 220884, held by Rubicon Research. Hydrochlorothiazide; Spironolactone.
As of Nov 16, 2026, ANDA 220884 (Spironolactone And Hydrochlorothiazide), held by Rubicon Research, was first approved by FDA on Sep 10, 2026, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 10, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Spironolactone And Hydrochlorothiazide25MG;25MG · tablet;oral | Hydrochlorothiazide; Spironolactone | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters